HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.

Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. · 2015

Read HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. by Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4511072.txt.

Description

Eric Van Cutsem and Yung-Jue Bang lead a long author list reporting screening data from the ToGA trial in Gastric Cancer. ToGA tested trastuzumab, a targeted drug, plus standard chemotherapy in stomach and junction cancers that make too much HER2, a growth protein. Patients on the drug lived longer. The screening set behind the trial is the largest of its kind for this cancer.

Roughly one tumor sample in five tested HER2-positive. Rates were alike in European and Asian patients. Intestinal-type tumors scored far higher than diffuse-type ones, at about one in three against about one in sixteen. Junction tumors also scored higher than stomach tumors. The breakdown helps labs and doctors know where HER2 testing is most likely to find patients the drug can help.

Catalog record

CREATORVan Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4511072

Browse the full library · About the Tower of Babel